Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.39 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2914214 | 0.89 | NTRK1 (0.42) | NTRK1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2921460 | 0.87 | SMN1; SMN2 (0.42) | PARP1NTRK1NPC1RAB9ANR1H4 | |
| SCHEMBL2916667 | 0.86 | LMNA (0.41) | NPC1RAB9AALDH1A1TP53 | |
| SCHEMBL2921797 | 0.86 | NTRK1 (0.42) | NTRK1NPC1RAB9AALDH1A1CCNA2 | |
| SCHEMBL2921189 | 0.86 | KMT2A (0.43) | PARP1NTRK1KDM4EALDH1A1NPSR1 | |
| SCHEMBL2919755 | 0.86 | KMT2A (0.41) | NTRK1BCHENPC1RAB9AKDM4E | |
| SCHEMBL2917089 | 0.86 | RAB9A (0.46) | NTRK1BCHENPC1RAB9A | |
| SCHEMBL2923128 | 0.86 | NPC1 (0.45) | PARP1NTRK1NPC1RAB9AKDM4E | |
| SCHEMBL2922202 | 0.86 | KMT2A (0.48) | NTRK1NPC1RAB9AALDH1A1NPSR1 | |
| SCHEMBL2919737 | 0.86 | NTRK1 (0.45) | NTRK1NPC1RAB9AKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | claimed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | claimed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | claimed |
| US-8273765-B2 | Bicyclo-pyrazoles and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2012-09-25 | — | — | US | disclosed |
| EP-1320531-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2010-09-08 | — | — | EP | disclosed |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | PFIZER ITALIA S.R.L. (IT) | 2009-09-03 | — | — | US | disclosed |
| US-7541354-B2 | Bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-06-02 | — | — | US | disclosed |
| US-7531531-B2 | Method of treating diseases associated with altered kinase activity with bicyclo-pyrazoles | PFIZER ITALIA S.R.L. (IT) | 2009-05-12 | — | — | US | disclosed |
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-08-16 | — | — | US | disclosed |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191386-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | PARP1 891/4885NTRK1 2610/4885BCHE 4120/4885 |
| US-20090221632-A1 | Bicyclo-Pyrazoles and Pharmaceutical Compositions Comprising Them | MAP3K20, PLK2, PRKAA1 | PARP1 949/4885NTRK1 4175/4885BCHE 4221/4885 |
| US-20030171357-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K19, MAP3K1 | PARP1 891/4885NTRK1 2610/4885BCHE 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.